Current and emerging treatment options for ANCA-associated vasculitis: potential role of belimumab and other BAFF/APRIL targeting agents.
about
Granulomatosis With Polyangiitis in Otolaryngologist Practice: A Review of Current KnowledgeBelimumab in Systemic Lupus Erythematosus.Spotlight on blisibimod and its potential in the treatment of systemic lupus erythematosus: evidence to dateBAFF- and APRIL-targeted therapy in systemic autoimmune diseases.Advances in Biomarker-Guided Therapy for Pediatric- and Adult-Onset Neuroinflammatory Disorders: Targeting Chemokines/Cytokines.Therapeutic Management of Pediatric Antineutrophil Cytoplasmic Antibody (ANCA)-Associated Vasculitis
P2860
Current and emerging treatment options for ANCA-associated vasculitis: potential role of belimumab and other BAFF/APRIL targeting agents.
description
2015 nî lūn-bûn
@nan
2015 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2015 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
name
Current and emerging treatment ...... r BAFF/APRIL targeting agents.
@ast
Current and emerging treatment ...... r BAFF/APRIL targeting agents.
@en
Current and emerging treatment ...... r BAFF/APRIL targeting agents.
@nl
type
label
Current and emerging treatment ...... r BAFF/APRIL targeting agents.
@ast
Current and emerging treatment ...... r BAFF/APRIL targeting agents.
@en
Current and emerging treatment ...... r BAFF/APRIL targeting agents.
@nl
prefLabel
Current and emerging treatment ...... r BAFF/APRIL targeting agents.
@ast
Current and emerging treatment ...... r BAFF/APRIL targeting agents.
@en
Current and emerging treatment ...... r BAFF/APRIL targeting agents.
@nl
P2860
P921
P356
P1476
Current and emerging treatment ...... r BAFF/APRIL targeting agents.
@en
P2093
Aleksander Lenert
Petar Lenert
P2860
P304
P356
10.2147/DDDT.S67264
P407
P577
2015-01-07T00:00:00Z